Kristen Soto1, Susan Petit, James L Hadler. 1. Connecticut Department of Public Health, Emerging Infections Program, Hartford, CT 06134-0308, USA. Kristen.Soto@ct.gov
Abstract
OBJECTIVES: We compared invasive pneumococcal disease (IPD) incidence by race/ethnicity and neighborhood poverty level and assessed their relative utility to describe disparities in IPD in 1998-1999 and again in 2007-2008, after introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). METHODS: We conducted laboratory surveillance for pneumococcal isolates from sterile body sites and serotyped the isolates. Home address was geocoded to the census-tract level. Census-tract data on the percentage of people below poverty were grouped into three categories. The difference in the magnitude of incidence by race/ethnicity and by census-tract socioeconomic status (SES) (high poverty minus low poverty) was compared for 1998-1999 and 2007-2008 for PCV7 and non-PCV7 serotypes. RESULTS: In 1998-1999, incidence difference (all per 100,000 population) for PCV7 serotypes for black people compared with white people was 14.3 and by poverty level was 13.9. The highest rate was among white people in high-poverty tracts (77.3). By 2007-2008, there were only slight differences between rates for black and white people (0.7) and SES (1.4). In 1998-1999, the incidence difference for non-PCV7 serotypes was 4.7 between black and white people and 6.0 by SES. By 2007-2008, the differences were 11.6 and 11.7, respectively. Among those living in the highest-poverty tracts, white people had the highest rate (42.9). CONCLUSIONS: In the absence of vaccine, IPD incidence is higher among people living in higher-poverty census tracts and among black people. Emerging serotypes also follow this trend. Differences in neighborhood poverty levels reveal disparities in rates of IPD as large as those seen by race/ethnicity and could be used to routinely describe disparities and target prevention.
OBJECTIVES: We compared invasive pneumococcal disease (IPD) incidence by race/ethnicity and neighborhood poverty level and assessed their relative utility to describe disparities in IPD in 1998-1999 and again in 2007-2008, after introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). METHODS: We conducted laboratory surveillance for pneumococcal isolates from sterile body sites and serotyped the isolates. Home address was geocoded to the census-tract level. Census-tract data on the percentage of people below poverty were grouped into three categories. The difference in the magnitude of incidence by race/ethnicity and by census-tract socioeconomic status (SES) (high poverty minus low poverty) was compared for 1998-1999 and 2007-2008 for PCV7 and non-PCV7 serotypes. RESULTS: In 1998-1999, incidence difference (all per 100,000 population) for PCV7 serotypes for black people compared with white people was 14.3 and by poverty level was 13.9. The highest rate was among white people in high-poverty tracts (77.3). By 2007-2008, there were only slight differences between rates for black and white people (0.7) and SES (1.4). In 1998-1999, the incidence difference for non-PCV7 serotypes was 4.7 between black and white people and 6.0 by SES. By 2007-2008, the differences were 11.6 and 11.7, respectively. Among those living in the highest-poverty tracts, white people had the highest rate (42.9). CONCLUSIONS: In the absence of vaccine, IPD incidence is higher among people living in higher-poverty census tracts and among black people. Emerging serotypes also follow this trend. Differences in neighborhood poverty levels reveal disparities in rates of IPD as large as those seen by race/ethnicity and could be used to routinely describe disparities and target prevention.
Authors: Catherine A Lexau; Ruth Lynfield; Richard Danila; Tamara Pilishvili; Richard Facklam; Monica M Farley; Lee H Harrison; William Schaffner; Arthur Reingold; Nancy M Bennett; James Hadler; Paul R Cieslak; Cynthia G Whitney Journal: JAMA Date: 2005-10-26 Impact factor: 56.272
Authors: Nancy Krieger; Jarvis T Chen; Pamela D Waterman; David H Rehkopf; S V Subramanian Journal: Am J Public Health Date: 2005-02 Impact factor: 9.308
Authors: Brendan Flannery; Richard T Heffernan; Lee H Harrison; Susan M Ray; Arthur L Reingold; James Hadler; William Schaffner; Ruth Lynfield; Ann R Thomas; Jianmin Li; Michael Campsmith; Cynthia G Whitney; Anne Schuchat Journal: Ann Intern Med Date: 2006-01-03 Impact factor: 25.391
Authors: A Schuchat; T Hilger; E Zell; M M Farley; A Reingold; L Harrison; L Lefkowitz; R Danila; K Stefonek; N Barrett; D Morse; R Pinner Journal: Emerg Infect Dis Date: 2001 Jan-Feb Impact factor: 6.883
Authors: Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat Journal: N Engl J Med Date: 2003-05-01 Impact factor: 91.245
Authors: Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson Journal: JAMA Date: 2007-04-25 Impact factor: 56.272
Authors: Brendan Flannery; Stephanie Schrag; Nancy M Bennett; Ruth Lynfield; Lee H Harrison; Arthur Reingold; Paul R Cieslak; James Hadler; Monica M Farley; Richard R Facklam; Elizabeth R Zell; Cynthia G Whitney Journal: JAMA Date: 2004-05-12 Impact factor: 56.272
Authors: Lauri A Hicks; Lee H Harrison; Brendan Flannery; James L Hadler; William Schaffner; Allen S Craig; Delois Jackson; Ann Thomas; Bernard Beall; Ruth Lynfield; Arthur Reingold; Monica M Farley; Cynthia G Whitney Journal: J Infect Dis Date: 2007-10-04 Impact factor: 5.226
Authors: Matthew R Moore; Robert E Gertz; Robyn L Woodbury; Genevieve A Barkocy-Gallagher; William Schaffner; Catherine Lexau; Kenneth Gershman; Arthur Reingold; Monica Farley; Lee H Harrison; James L Hadler; Nancy M Bennett; Ann R Thomas; Lesley McGee; Tamara Pilishvili; Angela B Brueggemann; Cynthia G Whitney; James H Jorgensen; Bernard Beall Journal: J Infect Dis Date: 2008-04-01 Impact factor: 5.226
Authors: Nancy Krieger; Jarvis T Chen; Pamela D Waterman; David H Rehkopf; S V Subramanian Journal: Am J Public Health Date: 2003-10 Impact factor: 9.308
Authors: Jennifer E DeVoe; Andrew W Bazemore; Erika K Cottrell; Sonja Likumahuwa-Ackman; Jené Grandmont; Natalie Spach; Rachel Gold Journal: Ann Fam Med Date: 2016-03 Impact factor: 5.166
Authors: Jessica A Kattan; Kathy S Kudish; Betsy L Cadwell; Kristen Soto; James L Hadler Journal: Am J Public Health Date: 2013-11-14 Impact factor: 9.308
Authors: James L Hadler; Paula Clogher; Jennifer Huang; Tanya Libby; Alicia Cronquist; Siri Wilson; Patricia Ryan; Amy Saupe; Cyndy Nicholson; Suzanne McGuire; Beletshachew Shiferaw; John Dunn; Sharon Hurd Journal: Open Forum Infect Dis Date: 2018-07-03 Impact factor: 3.835
Authors: Ramal Moonesinghe; Eleanor Fleming; Benedict I Truman; Hazel D Dean Journal: Int J Environ Res Public Health Date: 2012-09-03 Impact factor: 3.390
Authors: Candis M Hunter; Simone W Salandy; Jessica C Smith; Chris Edens; Brian Hubbard Journal: Public Health Rep Date: 2021-06-29 Impact factor: 3.117
Authors: Gayle Langley; William Schaffner; Monica M Farley; Ruth Lynfield; Nancy M Bennett; Arthur Reingold; Ann Thomas; Lee H Harrison; Megin Nichols; Susan Petit; Lisa Miller; Matthew R Moore; Stephanie J Schrag; Fernanda C Lessa; Tami H Skoff; Jessica R MacNeil; Elizabeth C Briere; Emily J Weston; Chris Van Beneden Journal: Emerg Infect Dis Date: 2015-09 Impact factor: 6.883